Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.46 |
| ▸ | ADH1C | P00326 | 1/20 | 0.46 |
| ▸ | ADH1A | P07327 | 1/20 | 0.46 |
| ▸ | ADH4 | P08319 | 1/20 | 0.46 |
| ▸ | ADH7 | P40394 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8628188 | 1.00 | ADH1B (0.46) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL28318789 | 0.92 | ADH1B (0.56) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL20366018 | 0.92 | ADH1B (0.56) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL17706682 | 0.88 | CHRM1 (0.44) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL14819043 | 0.88 | CHRM1 (0.44) | ADH1BADH1CADH1AADH4ADH7 | |
| Leucine SCHEMBL6461855 | 0.84 | SLC7A5 (0.51) | NOD1SLC15A1SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL20806152 | 0.83 | DPP7 (0.42) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL4955832 | 0.83 | HDAC2 (0.40) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL13351177 | 0.81 | MME (0.45) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL13350786 | 0.81 | SLC15A1 (0.43) | ADH1BADH1CADH1AADH4ADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2813512-B1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-03-31 | — | — | EP | claimed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | claimed |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-03-19 | — | — | US | claimed |
| EP-2813512-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | Chugai Seiyaku Kabushiki Kaisha (JP) | 2014-12-17 | — | — | EP | claimed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| EP-3860956-B1 | PROCESS FOR MANUFACTURING N-ALKYL-DIPHOSPHONATE AMINO AMINOACIDS | ITALMATCH CHEMICALS SPA (IT) | 2024-11-27 | — | — | EP | disclosed |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-23 | — | — | US | disclosed |
| US-11891457-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-06 | — | — | US | disclosed |
| CN-116615556-A | Use of DEXTRAMER in single cell assays | 贝克顿迪金森公司 | 2023-08-18 | — | — | CN | disclosed |
| CN-114641311-A | anti-TNFR 2 antibodies and methods of use thereof | 埃派斯进有限公司 | 2022-06-17 | — | — | CN | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
| EP-2813512-B1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-03-31 | — | — | EP | disclosed |
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-03-19 | — | — | US | disclosed |
| EP-2813512-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | Chugai Seiyaku Kabushiki Kaisha (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-5811394-A | CAN BE TARGETED TO SPECIFIC SITES | DIATIDE, INC. (US) | 1998-09-22 | — | — | US | disclosed |
| US-5788960-A | RADIOLOGY; DIAGNOSTIC AGENTS | DIATECH, INC. (US) | 1998-08-04 | — | — | US | disclosed |
| US-5681541-A | (OLIGO OR POLY)PEPTIDES | DIATIDE, INC. (US) | 1997-10-28 | — | — | US | disclosed |
| US-5654272-A | INCLUDING AN AMINO ACID SEQUENCE OF CYSTEINE-(AMINO ACID)-CYSTEINE TO COMPLEX THE ISOTOPE AND A TARGET BINDING SEQUENCEFOR TARGET SITES INCLUDING ATHEROSCLEROTIC PLAQUE AND ALZHEIMER'S AMYLOID PLAQUE; SCINTIGRAPHY | DIATIDE, INC. (US) | 1997-08-05 | — | — | US | disclosed |
| US-5451663-A | Fluorescent dyes | MOLECULAR PROBES, INC. (US) | 1995-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11891457-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | ADH1B 4832/4885ADH1C 4793/4885ADH1A 4885/4885 |
| US-20240166689-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | ADH1B 4832/4885ADH1C 4793/4885ADH1A 4885/4885 |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | ADH1B 4832/4885ADH1C 4793/4885ADH1A 4885/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | ADH1B 4832/4885ADH1C 4793/4885ADH1A 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.